This study compared the effectiveness of docetaxel (DOC; Taxotere) to abiraterone (ABI; Zytiga) and assessed possible predictive markers of progression-free survival (PFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The authors concluded that under real-world conditions, ABI was associated with better PFS in these patients.

This study examined the risk of heart-related mortality in patients undergoing androgen-deprivation therapy (ADT) for prostate cancer. It found that patients treated with radiation therapy and ADT did not have an increased risk of heart-related mortality.

This study evaluated the effectiveness of salvage radiotherapy (RT) in patients with recurrence of prostate cancer (PCa) after prostate surgery. The study found that salvage RT was effective in the management of PCa recurrence with manageable side effects.

This study reported the long-term effectiveness and safety outcomes of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The data showed that this combination improved survival, delayed castration resistance, and maintained the quality of life in these patients.

This study compared the outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer. The study found that the RARP approach was associated with better outcomes compared to LRP.

This study reviewed the effectiveness and safety of lutetium-177 [177Lu]-prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that PRLT was associated with good outcomes and manageable side effects.

This study investigated the effectiveness and safety of re-irradiation in the treatment of patients with relapsed prostate cancer (PCa). The data showed that the use of re-irradiation in these patients was associated with good outcomes and low toxicity.

This study compared the outcomes of Retzius-sparing (RS) robotic-assisted laparoscopic prostatectomy (RALP) with standard RALP (sRALP) for the treatment of patients with localized prostate cancer (PCa). The study found that the RS-RALP approach may be associated with better urinary outcomes compared to sRALP.

This study evaluated patient-reported outcomes in men with non-metastatic castration-resistant prostate cancer (CRPC) when treated with either enzalutamide (Xtandi) or a placebo. The data showed that enzalutamide treatment delayed the time until pain progression and improved the quality of life of patients compared to a placebo.

This study compared the patient-reported quality of life outcomes between conventionally fractionated radiation treatment (CFRT) and ultra-hypofractionated radiation treatment (UHFRT) in patients with localized prostate cancer. The data showed that both radiotherapy techniques led to similar long-term outcomes.